- Abenavoli L, et al. Milk thistle in liver diseases: Past, present, future. Phytother Res. 2010; 24(10): 1423-1432.
- Gu X, et al. Molecular mechanisms underlying chemical liver injury. Expert Rev Mol Med. 2012; 14: e4.
- Gerber LH, et al. Importance of fatigue and its measurement in chronic liver disease. World J Gastroenterol. 2019; 25(28): 3669-3683.
- Acharya C, Bajaj J. Gut microbiota and complications of liver disease. Gastroenterol Clin North Am. 2017; 46(1): 155-169.
- Crocenzi FA, et al. Effect of silymarin on biliary bile salt secretion in the rat. Biochem Pharmacol. 2000; 59(8): 1015-1022.
- Karimi G, et al. “Silymarin”, a promising pharmacological agent for treatment of diseases. Iran J Basic Med Sci. 2011; 14(4): 308-317.
- Pradhan SC, Girish C. Hepatoprotective herbal drug, silymarin from experimental pharmacology to clinical medicine. Indian J Med Res. 2006; 124(5): 491-504.
- Dixit N, et al. Silymarin: A review of pharmacological aspects and bioavailability enhancement approaches. Indian J Pharmacol. 2007; 39(4): 172-179.
- Vargas-Mendoza N, et al. Hepatoprotective effect of silymarin. World J Hepatol. 2014; 6(3): 144-149.
- Surai PF. Silymarin as a natural antioxidant: An overview of the current evidence and perspectives. Antioxidants (Basel). 2015; 4(1): 204-247.
- Kim EJ, et al. Silymarin inhibits morphological changes in LPS-stimulated macrophages by blocking the NF-κB pathway. Korean J Physiol Pharmacol. 2015; 19(3): 211-218.
- Lovelace ES, et al. Silymarin suppresses cellular inflammation by inducing reparative stress signaling. J Nat Prod. 2015; 78(8): 1990-2000.
- Esmaeil N, et al. Silymarin impacts on immune system as an immunomodulator: One key for many locks. Int Immunopharmacol. 2017; 50: 194-201.
- Choi YH and Yan GH. Silibinin attenuates mast cell-mediated anaphylaxis-like reactions. Biol Pharm Bull. 2009; 32(5): 868-875.
- Liu CH, et al. Antiviral activities of silymarin and derivatives. Molecules. 2019; 24(8): 1552.
- de Oliveira DR, et al. In vitro antimicrobial and modulatory activity of the natural products silymarin and silibinin. Biomed Res Int. 2015; 2015: 292797.
- Federico A, et al. Silymarin/silybin and chronic liver disease: A marriage of many years. Molecules. 2017; 22(2): 191.
- El-Lakkany NM, et al. Anti-inflammatory/anti-fibrotic effects of the hepatoprotective silymarin and the schistosomicide praziquantel against Schistosoma mansoni-induced liver fibrosis. Parasit Vectors. 2012; 5: 9.
- Perez-Sanchez A, et al. Intestinal permeability study of clinically relevant formulations of Silibinin in Caco-2 Cell monolayers. Int J Mol Sci. 2019; 20(7): 1606.
- Kumar N, et al. Silymarin liposomes improves oral bioavailability of silybin besides targeting hepatocytes, and immune Cells. Pharmacol Rep. 2014; 66(5): 788-798.
- Ahn H, et al. Liposomal delivery systems for intestinal lymphatic drug transport. Biomater Res. 2016; 20: 36.
- Alyautdin R, et al. Nanoscale drug delivery systems and the blood-brain barrier. Int J Nanomedicine. 2014; 9: 795-811.
- Spector AA, et al. Membrane lipid composition and cellular function. J Lipid Res. 1985; 26(9): 1015-1035.
Free Shipping on Orders over $300 (Excludes , , )
